Skip to main content
. 2014 Jan 3;7:2. doi: 10.1186/1756-8722-7-2

Table 4.

The summary of studies of HAG regimen for AML, high-risk MDS and MDS/AML

Reference Patients type No. CR, %
Wei 2006 [[76]]
Refractory or relapsed AML
20
70.0
Zhang 2008 [[77]]
Refractory or relapsed AML
36
50.0
Ji 2010 [[78]]
Refractory or relapsed AML
37
46.0
Gu 2011 [[79]]
Refractory or relapsed AML
67
52.2
Liu 2006 [[80]]
Elderly AML
31
58.1
Shu 2007 [[84]]
MDS-RAEB
28
53.6
Su 2008 [[85]]
High-risk MDS or MDS/AML
33
46.7
Wu 2009 [[86]]
High-risk MDS or MDS/AML
32
46.9
Wu 2011 [[87]] Elderly high-risk MDS or MDS/AML 33 57.6

HAG homoharringtonine + arabinoside + G-CSF, CR complete remission, AML acute myeloid leukemia, MDS myelodysplastic syndrome.

MDS/AML MDS evolving to AML.